Q BioMed's bone pain drug Strontium89 sees Medicare reimbursement rate upped

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the Centers for Medicare and Medicaid Services (CMS) updated the reimbursement rate for its metastatic bone pain drug Strontium89, making it more easily available to Medicare patients.

Corin says with the CMS update, all Medicare providers are now able to be reimbursed appropriately for providing Strontium89 treatment, giving Q BioMed the ability to engage with hospitals and providers throughout the US and a potential increase in the use of Strontium89.